Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice
Related Experiment Video
Updated: Nov 10, 2025
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Celine Jacobs1, Lore Lapeire1,2
1Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium.
Abstract:
Soft tissue sarcomas are a group of rare mesenchymal tumors with more than 70 subtypes described. Treatment of these subtypes in an advanced setting is mainly according to a one-size-fits-all strategy indicating a high unmet need of new and more targeted therapeutic options in order to optimize survival. The introduction of advanced molecular techniques in cancer has led to better diagnostics and identification of new therapeutic targets, leading to more personalized treatment and improved prognosis for several cancer types. In sarcoma, a likewise evolution is seen, albeit at a slower pace. This manuscript describes how in the past years advanced molecular profiling in soft tissue sarcomas was able to identify specific and often pathognomonic aberrations, deferring standard sarcoma treatment in favor of more targeted treatment from an oncologist's point of view.
Insights
Soft tissue sarcomas require targeted therapies due to rare subtypes and limited treatment options. Advanced molecular profiling is identifying specific aberrations for personalized treatment, improving patient outcomes.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Soft tissue sarcomas are rare mesenchymal tumors with over 70 subtypes.
- Current advanced-stage treatment follows a generalized approach, highlighting a need for targeted therapies.
- Personalized medicine advances in other cancers offer a model for sarcoma treatment evolution.
Purpose of the Study:
- To review the impact of advanced molecular profiling in soft tissue sarcomas.
- To highlight the identification of specific genetic aberrations in sarcoma subtypes.
- To discuss the shift towards targeted therapeutic strategies in sarcoma oncology.
Main Methods:
- Review of recent literature on molecular profiling in soft tissue sarcomas.
- Analysis of identified genetic aberrations and their clinical relevance.
- Discussion of targeted treatment implications from an oncologist's perspective.
Main Results:
- Advanced molecular profiling has identified specific, often pathognomonic, aberrations in soft tissue sarcomas.
- These findings support a move away from uniform treatment protocols.
- Personalized therapeutic strategies are emerging as a viable alternative.
Conclusions:
- Molecular profiling is crucial for understanding soft tissue sarcoma heterogeneity.
- Targeted therapies based on specific molecular aberrations promise improved outcomes.
- Oncologists can leverage molecular data for more precise sarcoma treatment decisions.
